CPX-351 血液恶性病和功能障碍的成年人中的药理动力学和安全性:第一阶段试验
Scott R Solomon1, Bayard L Powell2, Jamie Koprivnikar3
1Bone & Marrow Transplant (BMT), Leukemia and Cellular Immunotherapy Programs, Northside Hospital Cancer Institute, Atlanta, GA 30342, USA.
CPX-351的药理动力学和安全性在患有血液恶性瘤和功能变化的患者中进行了评估. 在中度或重度功能障碍患者中,不需要对CPX-351进行剂量调整.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- CPX-351是一种用于血液恶性瘤的研究化疗.
- 功能可能会影响药物的药理动力学和安全性.
- 功能障碍对CPX-351的影响尚未完全描述.
研究的目的:
- 评估CPX-351的药理动力学 (PK) 和安全性在患有血液恶性瘤和正常或功能受损的患者中.
- 评估不同程度的功能障碍对CPX-351药物暴露和代谢物水平的影响.
- 为了确定CPX-351的剂量调整是否对于患有功能障碍的患者是必要的.
主要方法:
- 一项开放式的第一阶段研究 (NCT03555955) 将血液恶性瘤患者根据肌素清除率 (CrCl) 分为三个队列:正常 (≥90毫升/分钟),中度 (30至<59毫升/分钟) 和严重 (<30毫升/分钟).
- 患者接受了静脉注射CPX-351作为最初的诱导疗法.
- 采集了血液和尿液样本,用于对细胞arabine, daunorubicin 和它们的代谢物 (arabinosyluracil [Ara-U], daunorubicinol) 的PK分析.
主要成果:
- 功能不良并没有显著改变细胞氨基,鲁素或鲁醇的暴露.
- 在患有功能障碍的患者中,观察到阿拉比诺西卢拉 (Ara-U) 暴露的轻微增加.
- 在所有功能组中,CPX-351的安全性概况相似,常见的治疗出现的不良事件包括发烧性中性质减退,恶心和高血糖症. 没有报告因不良事件而停止治疗.
结论:
- 中度或重度功能障碍对CPX-351的药理动力学没有显著的影响.
- 在正常和功能受损的患者中,CPX-351的安全性概况与正常和功能受损的患者相似.
- 对于患有血液性恶性瘤,患有中度或重度功能障碍的患者,不需要调整CPX-351的剂量.
更多相关视频
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
